Ablynx reports phase II dara for ALX-0081 in high risk ACS patients undergoing a PCI procedure
16-Nov-2011 -
Ablynx announced head-line data from a proof-of-concept (POC) Phase II study with the anti-vWF Nanobody, ALX-0081, in high risk patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In this multi-national, multi-institutional, open-label Phase II study, ...
Ablynx
Acute Coronary Syndrome
percutaneous coronary intervention
+1